Neko Health: $700 Million for AI Scans in the USA

Neko Health: A Massive Fundraising Round to Establish Itself in the United States

Neko Health, a company specializing in AI-assisted body scans, has raised an impressive $700 million. This funding will be used to expand its services to the United States, with the opening of its first clinic in New York planned. Neko's service combines several cutting-edge technologies, including medical imaging, blood analyses, proprietary sensors, and clinician reviews to provide comprehensive preventive screening.

This Series C funding round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Among the investors are also established players like Atomico, General Catalyst, and Lakestar, as well as newcomers such as Liberty City Ventures, Positive Sum, and BDT & MSD.

David Ofer, a representative of O.G. Venture Partners, is expected to join Neko's board of directors, pending regulatory approval. With this latest funding round, Neko's total funding since 2023 now exceeds $1 billion. The company previously raised $65 million in a Series A round in 2023, followed by $260 million in January 2025.

Influential figures such as Mark Zuckerberg and Priscilla Chan, former tennis player Maria Sharapova, musician will.i.am, and former footballer Thierry Henry have also invested in this round. Among existing individual investors are Reddit co-founder Alexis Ohanian and actress Zoë Saldaña.

How Neko Health's AI Body Scans Work

Neko Health clinics offer an integrated approach that combines full body scans, blood analyses, artificial intelligence, and custom medical equipment. This service aims to detect early signs of diseases such as skin cancer, cardiovascular diseases, and diabetes.

Neko describes its service as a non-invasive, radiation-free health assessment lasting 60 minutes. Using proprietary sensors and blood analysis, the service examines various health indicators, including skin conditions, blood anomalies, and risk factors for diseases like metabolic syndrome, strokes, and heart attacks.

The scan also includes an electrocardiogram, arterial measurements, a body composition analysis, as well as over 2,000 high-resolution images to map a client's skin. Blood samples are processed directly at the clinic, allowing results to be discussed during the same visit with a healthcare professional.

While many measurements such as blood pressure, blood sugar, and cholesterol are available through conventional health services, Neko integrates them with proprietary imaging, automated data collection, and on-site blood processing to provide a comprehensive clinical consultation in a single appointment.

The company's public clinical documents do not include a comparative study demonstrating whether this combined approach improves clinical outcomes or cost-effectiveness compared to traditional preventive care pathways.

Expansion and Service Costs

The recently secured funding will allow Neko to open clinics in New York and other U.S. cities, although additional locations and the timeline for expansion have not yet been specified. A waiting list for the New York clinic is already available on the company's website, but the cost of scans in the United States has not been disclosed.

Currently, Neko operates eight clinics in the UK and Sweden, with locations in Stockholm, Manchester, Birmingham, and London. The cost of a scan is £299 in the UK and 2,750 Swedish kronor in Sweden, approximately $400 and $285 respectively.

Since launching its service in 2023, Neko has conducted 100,000 scans, and over 350,000 people have signed up for a scan or joined waiting lists. According to the company, 75% of clients book and prepay for another scan at the end of their appointment, allowing clinicians to track the evolution of measurements and skin images over time.

Public information does not specify whether annual screening is the appropriate interval for each age or risk group. Founded in 2018 by Spotify co-founder Daniel Ek and CEO Hjalmar Nilsonne, Neko operated quietly until the launch of its service in 2023.

Technological and Clinical Innovations

Neko has recently enhanced its services with body composition measurements and clinician reviews of data from wearable devices. Additionally, the company has introduced updated versions of its medical devices Derma, Echo, and Spectrum, which collect information on skin, heart function, and blood circulation.

These new devices allow for capturing a larger volume of health data and further automating the scanning process. Neko plans to deploy these devices in its clinics in the coming months.

The clinic model requires proprietary equipment, blood processing capabilities, medical staff, and specialized review for certain findings. Neko stated that its Covent Garden clinic, with seven rooms, was designed to support tens of thousands of annual scans, but it has not disclosed capacity or staffing figures for its planned locations in the United States.

Regulation and Access in the United States

FDA records show that two of the devices developed by Neko received authorization through the 510(k) process in May 2026. Derma-2 was authorized as a complementary thermographic system, while Spectrum-2 was approved as a tissue saturation oximeter used in cardiovascular measurements.

These authorizations apply to the specified devices and their intended uses, rather than to the entire Neko Health Scan as an FDA-approved screening service.

Neko describes its U.S. clinics as providers of preventive health and wellness rather than full-service medical practices. Its privacy notice advises clients to continue consulting their existing clinicians for diagnoses and treatments, including for conditions identified by a Neko scan.

Neko's U.S. clinics are currently not participating in health insurance plans, and the company indicates that most of its services are not covered by a payer. Clients are therefore expected to pay directly for the initial assessment.

The company has not disclosed what clients would pay for diagnostic tests or treatments provided by external healthcare providers. It has also not announced its pricing in the U.S. or whether employers, insurers, or other organizations will subsidize access to the service.

Questions About Clinical Evidence

Publicly available information does not include a peer-reviewed study validating the entire screening service. A study registered on ClinicalTrials.gov evaluates the adequacy of Neko's multimodal skin imaging technology for screening and diagnostic support applications, including skin cancer and Raynaud's phenomenon.

The trial remains an ongoing evaluation and does not establish the clinical performance of the complete Neko Health Scan.

Neko's public documents do not disclose how often its scans produce false positive results, how many clients undergo additional procedures, or how many reported anomalies are subsequently considered clinically insignificant.

The company's privacy notice in the U.S. identifies an AI dictation system used to summarize medical records, questionnaires, scan data, and clinical conversations, as well as to draft reports. Neko claims that clinicians review the reports produced using this system.

Public information does not provide a comprehensive breakdown of scan measures or classifications that rely on AI, conventional software, or direct clinical assessment. It also does not specify that the AI independently diagnoses the conditions covered by the service.

FDA authorizations for individual devices do not establish the performance of each algorithm used to combine or interpret the resulting data. The public documents reviewed do not include detailed figures on the actual performance of each AI system used in the screening process.

The health outcome data reported by Neko is based on 1,469 clients who underwent a second scan approximately one year after their first. The company stated that this group recorded improvements in blood pressure, cholesterol, and blood sugar, while body weight remained generally stable.

The analysis scans were conducted at Neko clinics in Stockholm. The company divided the results into a general group, a healthy group, and groups covering clients suffering from hypertension, pre-diabetes, or diabetes.

Neko stated that the analysis was not a scientific study and did not include a control group. Clients may have started treatment or changed behavior between appointments, so the figures do not establish that the scans caused the reported improvements.

The analysis only covered clients who returned for a privately purchased second scan. Neko has not published demographic information showing how this group compares to its broader clientele or the general population.

The company has not disclosed its valuation following the latest round. The Financial Times, citing anonymous sources, reported that Neko is now valued at approximately $7 billion.